{"id":"bialamicol","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"camoform","offLabel":[],"synonyms":["bialamicol hydrochloride","bialamicol","camoform","biallylamicol","bialamicol HCl"],"timeline":[],"brandName":"Camoform","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells have locks on them, and Camoform is a key that fits into one of those locks. When it binds to the lock, it triggers a series of events that help to treat a particular condition. This is a simplified explanation of how Camoform works at a molecular level.","oneSentence":"Camoform works by interacting with a specific molecular target to produce a therapeutic effect.","technicalDetail":"Camoform's mechanism of action involves binding to a specific protein or receptor, which triggers a downstream signaling cascade that ultimately leads to its therapeutic effect. The exact molecular details of this process are not well understood and require further research."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/364","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BIALAMICOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:03:12.017811","biosimilars":[],"competitors":[],"genericName":"bialamicol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"TA5NM093QJ","CHEBI":"CHEBI:135712","INN_ID":"747","UMLSCUI":"C0301342","ChEMBL_ID":"CHEMBL1197792","KEGG_DRUG":"D03108","PUBCHEM_CID":"10304","SNOMEDCT_US":"83702003","SECONDARY_CAS_RN":"3624-96-2"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Camoform, also known as Bialamicol, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not FDA approved for any indications. The drug's pharmacokinetic properties, including half-life and bioavailability, are also unknown. Camoform is owned by an unspecified company, and its generic status is not confirmed. Further research is needed to understand its clinical applications and safety profile.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}